View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 15, 2022

Oncology networks partner to launch Exigent Research

By supporting oncology practices, the company will offer centralised services that speed up access to trials for patients.

Independent oncology networks the National Cancer Care Alliance (NCCA) and Quality Cancer Care Alliance (QCCA) have launched a new venture, Exigent Research, which comprises 25 independent practices to enhance cancer care. 

The introduction of this venture builds on the QCCA Research Network.

Exigent has been designed to offer centralised services that speed up access to clinical trials for patients by supporting these oncology practices which offer care for over 1.8 million people.

Furthermore, Exigent will be able to offer trials to member practices more rapidly than they can through conventional networks by centralising services such as contracting, budgeting and central IRB.

Leaving unique technology at its top potential, the venture boosts the expertise of each member practice by aiding them in detecting eligible national, regional and local trials.

In addition, this approach will help in including patients in the trials efficiently compared to what an individual practice member would require for supporting such a process. 

Exigent plans to continue the development of its expertise by collaborating with industry and offering access to a wider network of independent practices that aim to offer clinical research at the point of care in their communities.

Through the company, NCCA will be able to back first-in-human, Phase I-IV, pragmatic and accelerated trials on demand (ATOD) that benefit patients directly.

Exigent Research president and CEO Sibel Blau said: “We’ve been working hard to develop a proprietary centralised data warehouse supported by advanced technology that allows us to utilize real-time data coming from our practices every day so that we can better support the patients that need our care faster, smarter, and much more optimally than ever before. 

“As a result, times for enrolment into clinical trials are drastically reduced, creating a lifesaving advantage and democratizing clinical research for all patients regardless of where they live.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena